Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.43 - $17.02 $465,201 - $692,714
40,700 New
40,700 $527,000
Q3 2023

Nov 13, 2023

SELL
$11.09 - $22.13 $1.77 Million - $3.54 Million
-159,819 Closed
0 $0
Q2 2023

Aug 14, 2024

BUY
$20.68 - $39.85 $2.27 Million - $4.38 Million
109,914 Added 270.06%
150,614 $3.22 Million
Q2 2023

Aug 14, 2023

SELL
$20.68 - $39.85 $2.88 Million - $5.56 Million
-139,506 Closed
0 $0
Q1 2023

May 15, 2024

BUY
$38.82 - $54.59 $4.76 Million - $6.69 Million
122,614 New
122,614 $4.96 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $9.23 Million - $12.2 Million
226,419 New
226,419 $10.5 Million
Q3 2022

Nov 13, 2023

BUY
$48.29 - $71.27 $7.72 Million - $11.4 Million
159,819 New
159,819 $8.29 Million
Q2 2022

Aug 14, 2023

BUY
$38.13 - $76.93 $5.32 Million - $10.7 Million
139,506 New
139,506 $6.59 Million
Q1 2022

May 12, 2023

SELL
$56.06 - $74.11 $4.87 Million - $6.44 Million
-86,913 Reduced 38.39%
139,506 $9.93 Million
Q1 2022

May 09, 2022

SELL
$56.06 - $74.11 $6.97 Million - $9.22 Million
-124,344 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$60.19 - $97.37 $7.48 Million - $12.1 Million
124,344 New
124,344 $9.3 Million
Q3 2021

Nov 14, 2022

BUY
$41.02 - $58.65 $4.51 Million - $6.45 Million
109,936 New
109,936 $6.25 Million
Q3 2021

Nov 05, 2021

SELL
$41.02 - $58.65 $4.51 Million - $6.45 Million
-109,936 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$43.76 - $53.11 $4.81 Million - $5.84 Million
109,936 New
109,936 $4.84 Million
Q2 2021

Aug 10, 2021

SELL
$43.76 - $53.11 $5.64 Million - $6.85 Million
-128,914 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$41.69 - $54.95 $5.37 Million - $7.08 Million
128,914 New
128,914 $6.36 Million
Q1 2021

May 07, 2021

SELL
$41.69 - $54.95 $6.42 Million - $8.46 Million
-154,002 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$41.16 - $47.47 $6.34 Million - $7.31 Million
154,002 New
154,002 $6.48 Million
Q4 2020

Feb 10, 2021

SELL
$41.16 - $47.47 $6.57 Million - $7.58 Million
-159,694 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$43.36 - $53.53 $6.92 Million - $8.55 Million
159,694 New
159,694 $7.31 Million
Q3 2020

Nov 10, 2020

SELL
$43.36 - $53.53 $7.16 Million - $8.84 Million
-165,085 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$46.37 - $57.58 $7.65 Million - $9.51 Million
165,085 New
165,085 $8.29 Million
Q2 2020

Aug 07, 2020

SELL
$46.37 - $57.58 $9.79 Million - $12.2 Million
-211,132 Closed
0 $0
Q1 2020

May 07, 2021

BUY
$40.22 - $62.0 $8.49 Million - $13.1 Million
211,132 New
211,132 $10.9 Million
Q1 2020

May 08, 2020

SELL
$40.22 - $62.0 $8.49 Million - $13.1 Million
-211,132 Closed
0 $0
Q4 2019

Mar 03, 2020

BUY
$57.95 - $66.61 $12.2 Million - $14.1 Million
211,132 New
211,132 $13 Million
Q4 2019

Feb 12, 2020

SELL
$57.95 - $66.61 $12.2 Million - $14.1 Million
-211,132 Closed
0 $0
Q3 2019

Nov 13, 2020

BUY
$60.08 - $88.17 $12.7 Million - $18.6 Million
211,132 New
211,132 $12.7 Million
Q3 2019

Nov 08, 2019

SELL
$60.08 - $88.17 $12 Million - $17.6 Million
-199,146 Closed
0 $0
Q2 2019

Aug 13, 2020

BUY
$81.3 - $97.35 $16.2 Million - $19.4 Million
199,146 New
199,146 $16.8 Million
Q2 2019

Aug 09, 2019

SELL
$81.3 - $97.35 $15.3 Million - $18.3 Million
-188,301 Closed
0 $0
Q1 2019

May 11, 2020

BUY
$69.08 - $105.66 $6.08 Million - $9.3 Million
87,975 Added 87.69%
188,301 $18 Million
Q4 2018

Mar 04, 2019

BUY
$65.41 - $84.65 $6.56 Million - $8.49 Million
100,326 New
100,326 $7.11 Million
Q4 2018

Feb 08, 2019

SELL
$65.41 - $84.65 $5.71 Million - $7.39 Million
-87,248 Closed
0 $0
Q3 2018

Nov 12, 2019

BUY
$85.46 - $126.37 $7.46 Million - $11 Million
87,248 New
87,248 $7.46 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $177M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.